RenM, TangZ, WuX, et al.The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs. Sci Adv, 2019; 5:eaaw1391.
2.
House of Lords. History of the use of cannabis. In: Select Committee on Science and Technology. London: United Kingdom Parliament, 1998.
3.
BoireRG, FeeneyK. Medical Marijuana Law. Berkeley, CA: Ronin Publishing, 2007.
4.
PergamSA, WoodfieldMC, LeeCM, et al.Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer, 2017; 123:4488–4497.
5.
Van LanckerA, VelgheA, Van HeckeA, et al.Prevalence of symptoms in older cancer patients receiving palliative care: A systematic review and meta-analysis. J Pain Symptom Manage, 2014; 47:90–104.
6.
MittelA, HuaM. Supporting the geriatric critical care patient: Decision making, understanding outcomes, and the role of palliative care. Anesthesiol Clin, 2019; 37:537–546.
7.
BagshawSM, HagenNA. Medical efficacy of cannabinoids and marijuana: A comprehensive review of the literature. J Palliat Care, 2002; 18:111–122.
8.
SchorkNJ. Personalized medicine: Time for one-person trials. Nature, 2015; 520:609–611.
9.
SextonM, CuttlerC, FinnellJS, et al.A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis Cannabinoid Res, 2016; 1:131–138.
10.
National Academies ofScience, Engineering, andMedicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.
11.
WaissengrinB, UrbanD, LeshemY, et al.Patterns of use of medical cannabis among Israeli cancer patients: A single institution experience. J Pain Symptom Manage, 2015; 49:223–230.
12.
AggarwalSK. Use of cannabinoids in cancer care: Palliative care. Curr Oncol, 2016; 23:S33–S36.
13.
BachhuberMA, SalonerB, CunninghamCO, et al.Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med, 2014; 174:1668–1673.
14.
CyrC, ArboledaMF, AggarwalSK, et al.Cannabis in palliative care: Current challenges and practical recommendations. Ann Palliat Med, 2018; 7:463–477.
15.
The DC Center for Rational Prescribing (DCRx). Medical Cannabis: Evidence on Efficacy. 2019. Online document at: https://dchealth.dc.gov/dcrx, accessed January5, 2020.
16.
MaustDT, BonarEE, IlgenMA, et al.Agitation in Alzheimer disease as a qualifying condition for medical marijuana in the United States. Am J Geriatr Psychiatry, 2016; 24:1000–1003.
17.
PeprahK, McCormackS. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines. Ottawa ON: Canadian Agency for Drugs and Technologies in Health, 2019.
18.
BestardJA, TothCC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract, 2011; 11:353–368.
19.
NarangS, GibsonD, WasanAD, et al., Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain, 2008; 9:254–264.
20.
BlakeA, WanBA, MalekL, et al.A selective review of medical cannabis in cancer pain management. Ann Palliat Med, 2017; 6(Suppl. 2):S215–S222.
21.
BabsonKA, SottileJ, MorabitoD. Cannabis, cannabinoids, and sleep: A review of the literature. Curr Psychiatry Rep, 2017; 19:23.
